CUMULATIVE INDEX
Psychopharmacology Bulletin
A. Contents Index
Vol. 25, No. 1—1989

Annual NCDEU Meeting (1988)—Abridged Proceedings—

Establishing the Efficacy and Safety of Psychopharmacologic Drugs: The Role of the FDA and Industry

3 Introduction—*Nina R. Schooler*

5 The Review of Clinical Safety Data in a New Drug Application—*Thomas P. Laughren*

9 Diagnostic and Clinical Assessment Issues in the Development and Therapeutic Evaluation of Psychopharmacologic Agents—*Donald S. Robinson, Douglas L. Roberts, James E. Copp, and Ute Schwiderski*

Update on Treatment of Panic Disorder

17 Tricyclic Antidepressants and Monoamine Oxidase Inhibitors in the Treatment of Panic Disorder: Brief Review—*Michael R. Liebowitz*

21 Treatment of Panic Disorder: Nonbenzodiazepine Anxiolytics, Including Buspirone—*Donald S. Robinson, Rajesh C. Shrotriya, Donald R. Alms, Marianne Messina, and Joseph Andary*

27 Differential Effects of Imipramine and Behavior Therapy on Panic Disorder With Agoraphobia—*Matig Mavissakalian*

Serotonergic Agents in Obsessive-Compulsive Disorder

31 Fluvoxamine as an Antiobsessional Agent—*Wayne K. Goodman, Lawrence H. Price, Steven A. Rasmussen, George R. Heninger, and Dennis S. Charney*

36 Preliminary Results From a Multicenter Trial of Clomipramine in Obsessive-Compulsive Disorder—*Joseph DeVeaugh-Geiss, Phyllis Landau, and Richard Katz*

Tardive Dyskinesia: New Theories—New Treatments

41 Introduction—*S. Charles Schulz*

43 GABAmimetic Treatments for Tardive Dyskinesia: Efficacy and Mechanism—*Carol A. Tamminga, Gunvant K. Thaker, and James A. Nguyen*

47 The Plasma Phenylalanine/Large Neutral Amino Acid Ratio: A Risk Factor for Tardive Dyskinesia—*Mary Ann Richardson, Raymond Suckow, Rowland Whittaker, William Boggiano, Istvan Sziraki, Howard Kushner, and Authur Perumal*

52 Prospective Study of Tardive Dyskinesia in the Elderly—*Bruce L. Saltz, John M. Kane, Margaret G. Woerner, Jeffrey A. Lieberman, Jose Ma J. Alvir, Karen Blank, Kenneth Kahaner, and Cornelius Foley*

57 Clozapine Effects on Tardive Dyskinesia—*Jeffrey A. Lieberman, Bruce L. Saltz, Celeste A. Johns, Simcha Pollack, and John M. Kane*

Free Communications: Affective Disorders

63 A Placebo-Controlled Trial of L-Deprenyl in Atypical Depression—*Patrick J. McGrath, Jonathan W. Stewart, Wilma Harrison, Steven Wager, Edward N. Nunes, and Frederic M. Quitkin*

68 Fluvoxamine, Imipramine, and Placebo in the Treatment of Depressed Outpatients: Effects on Depression—*R. Bruce Lydiard, Lyle Knight Laird, W. Alex Morton, Jr., Thomas E. Steele, Charles Kellner, Michele T. Laraia, and James C. Ballenger*

71 Effect of Dose Escalation After Low-Dose Fluoxetine Therapy—*Bruce E. Dornseif, Stephen R. Dunlop, Janet H. Potvin, and J. F. Wernicke*

80 Vasopressin for ECT-Induced Memory Impairment: A Placebo-Controlled Comparison—*Jeffrey A. Mattes, Helen M. Pettinati, Stephani M. Nilsen, Sarah E. Robin, and Kenneth W. Willis*

Free Communications: Schizophrenia

85 Maintenance Imipramine Treatment Following Postpsychotic Depression—*Samuel G. Siris, Janis Cutler, Kim Owen, and Mary Paige Lang*

89 Plasma Homovanillic Acid as a Predictor of Response to Fluphenazine Treatment—*Theodore Van Putten, Stephen R. Marder, M. Aravagiri, Nicole Chabert, and Jim Mintz*

92 Treatment Outcome of First Episode Schizophrenia—*Jeffrey Lieberman, Darlene Jody, Stephen Geisler, Jacques Vital-Herne, Jose Ma J. Alvir, Joyce Walsleben, and Margaret G. Woerner*

97 Zotepine vs. Haloperidol in Paranoid Schizophrenia: A Double-Blind Trial—*W. Wolfgang Fleischhacker, Christian Barnas, Christoph H. Stuppäck, Barbara Unterweger, Carl Miller, and Hartmann Hinterhuber*

Free Communications: Childhood Disorders and Anxiety

101 Double-Blind, Placebo-Controlled Study of Nortriptyline in Depressed Children Using a "Fixed Plasma Level" Design—*Barbara Geller, Thomas B. Cooper, Harriet G. McCombs, Donna Graham, and Janet Wells*

109 Comparative Effects of Methylphenidate on Attention-Deficit Hyperactivity Disorder With and Without Aggressive/Noncompliant Features—*Rafael Klorman, Joan T. Brumaghim, Leonard F. Salzman, Jaine Strauss, Agneta D. Borgstedt, Margaret C. McBride, and Stuart Loeb*

114 Intravenous Pulse Loading of Clomipramine in Adolescents With Depression—*Floyd R. Sallee, Bruce G. Pollock, James M. Perel, Neal D. Ryan, and Richard L. Stiller*

119 Selective Monoamine Uptake Inhibitors and a Serotonin Antagonist in the Treatment of Panic Disorder—*Herman G.M. Westenberg and Johan A. den Boer*

124 Zolpidem: A New Imidazopyridine Hypnotic—*David Wheatley*

Free Communications: Disorders in the Elderly and Other Topics

129 Open-Trial Maintenance Nortriptyline in Geriatric Depression: Survival Analysis and Preliminary Data on the Use of REM Latency as a Predictor of Recurrence—*Charles F. Reynolds III, James M. Perel, Ellen Frank, Stanley Imber, and David J. Kupfer*

133 Differential Effects of Antihypertensive Medications on Cognitive Functioning—*Abraham Sudilovsky, Sydney Croog, Thomas Crook, Barry Turnbull, Marcia Testa, Sol Levine, and Gerald L. Klerman*

139 An Evaluation of Three Strategies for Interim Analysis in an Ongoing Study—*John E. Overall, Janet M. Gibson, and Scott L. Cecil*

144 Effects of Diazepam on Recall Memory: Relationship to Aging, Dose, and Duration of Treatment—*Nunzio Pomara, Dennis Deptula, Marietta Medel, Robert I. Block, and David J. Greenblatt*

149 Fenfluramine Treatment of Negative Symptoms in Older Schizophrenic Inpatients—*Larry D. Alphs, Jeff A. Lafferman, Louis Ross, Walter Bland, and Jerome Levine*

B1 Psychopharmacology—A Recurring Bibliography

CUMULATIVE INDEX
Psychopharmacology Bulletin
A. Contents Index
Vol. 25, No. 2—1989

Annual NCDEU Meeting (1988)—Poster Summaries—

159 The Negative Symptom Assessment: A New Instrument to Assess Negative Symptoms of Schizophrenia—*Larry D. Alphs, Ann Summerfelt, Helen Lann, and René Muller*

164 A Double-Blind, Placebo-Controlled Dose-Finding Study With Sertraline—*Mohammed Amin, Heinz Lehmann, and Jamal Mirmiran*

168 The Psychiatric Symptom Assessment Scale (PSAS)—*Llewellyn B. Bigelow and Bryan D. Berthot*

180 Subjective Symptoms: Part of the Negative Syndrome of Schizophrenia?—*Istvan Bitter, Judith Jaeger, Julita Agdeppa, and Jan Volavka*

186 Double-Blind Comparison of 3- and 6-mg Fixed Doses of Alprazolam vs. Placebo in Outpatients With Major Depressive Disorder—*Richard L. Borison, Dharmbeer Sinha, J. William Albrecht, Sharron Geber, and Bruce I. Diamond*

190 Efficacy and Safety of Tiospirone vs. Haloperidol and Thioridazine in a Double-Blind, Placebo-Controlled Trial—*Richard L. Borison, Dharmbeer Sinha, Susan Haverstock, Michael C. McLarnon, and Bruce I. Diamond*

194 Diagnostic Criteria and Behavior Patterns in Infantile Autism—*Magda Campbell and John E. Overall*

198 Bupropion in Children With Attention Deficit Disorder—*Charles D. Casat, Deborah Z. Pleasants, David H. Schroeder, and David W. Parler*

202 Lactate-Lowering Effect of Dichloroacetic Acid: A Model for Investigation of Anxiolytic Drugs?—*Stephen H. Curry*

204 The ACTH (4–9) Analog ORG 2766 in Panic Disorder: A Preliminary Study—*Johan A. den Boer, Herman G.M. Westenberg, Barbera Mastenbroek, and Jan M. van Ree*

209 Rebound Withdrawal Reactions Due to Clomipramine—*Bruce I. Diamond, Richard L. Borison, Richard Katz, and Joseph DeVeaugh-Geiss*

213 Alprazolam Intolerance in Stable Schizophrenic Outpatients—*Lisa Dixon, Peter J. Weiden, Allen J. Frances, and John Sweeney*

215 Drug Response Assessed by the Modified Maudsley Obsessive-Compulsive Inventory—*Roberto A. Dominguez, Alan F. Jacobson, Jose de la Gandara, Burton J. Goldstein, and Richard M. Steinbook*

219 A Comparison of Nefazodone, Imipramine, and Placebo in Patients With Moderate to Severe Depression—*John P. Feighner, Robert Pambakian, Richard C. Fowler, William F. Boyer, and M. Frances D'Amico*

222 The Hillside Akathisia Scale: A New Rating Instrument for Neuroleptic-Induced Akathisia—*W. Wolfgang Fleischhacker, Kenneth J. Bergmann, Robert Perovich, Linda K. Pestreich, Michael Borenstein, Jeffrey A. Lieberman, and John M. Kane*

227 Investigating Drug Plasma Levels and Clinical Response Using Random Regression Models—*Donald Hedeker, Robert D. Gibbons, Christine Waternaux, and John M. Davis*

232 A Descriptive Profile of the Depressed Child—*Carroll W. Hughes, Sheldon H. Preskorn, Elizabeth Weller, Ronald Weller, and Ruth Hassanein*

238 Parenteral S-Adenosyl-Methionine (SAMe) in Depression: Literature Review and Preliminary Data—*Philip G. Janicak, Joseph Lipinski, John M. Davis, Edward Altman, and Rajiv P. Sharma*

243 A Double-Blind, Placebo-Controlled Trial of Clonidine in the Treatment of Acute Mania—*Philip G. Janicak, Rajiv P. Sharma, Michael Easton, Joseph E. Comaty, and John M. Davis*

246 Direct Data Entry Using a Digitizing Tablet in Clinical Trials—*Jerome Levine and Ann Summerfelt*

250 Long-Term Followup of Patients on Managed Lithium Discontinuation—*George Molnar and Giovanni A. Fava*

253 Response to Clozapine in Chronic Psychotic Patients—*Richard R. Owen, Jr., Barbara J. Beake, David Marby, Eric C. Dessain, and Jonathan O. Cole*

257 Effect of Treatment With Antidepressants and Neuroleptics on Human Leukocyte Beta-Adrenergic Receptors—*Ghanshyam N. Pandey, Philip G. Janicak, Subhash C. Pandey, and John M. Davis*

263 Benzodiazepine Augmentation of Neuroleptic Treatment in Patients With Schizophrenia—*Carlos N. Pato, Owen M. Wolkowitz, Mark Rapaport, S. Charles Schulz, and David Pickar*

267 The Short- and Long-Term Efficacy of Paroxetine HCl: A. Data From a 6-Week Double-Blind Parallel Design Trial vs. Imipramine and Placebo—*Eric D. Peselow, Ann-Marie Filippi, Paul Goodnick, Faouzia Barouche, and Ronald R. Fieve*

272 The Short- and Long-Term Efficacy of Paroxetine HCl: B. Data From a Double-Blind Crossover Study and From a Year-Long Term Trial vs. Imipramine and Placebo—*Eric D. Peselow, Ann-Marie Filippi, Paul Goodnick, Faouzia Barouche, and Ronald R. Fieve*

277 GM1 Ganglioside as a Potential Treatment in Tardive Dyskinesia—*Eric D. Peselow, Shirley Irons, John Rotrosen, Teresa Alonso, and Frank Dorsey*

281 Therapeutic Drug Monitoring of Tricyclic Antidepressants: A Standard of Care Issue—*Sheldon H. Preskorn, George S. Jerkovich, Jorge H. Beber, and Pam Widener*

285 Attention Deficit Hyperactivity Disorder and Methylphenidate: The Relationship Between Gross Body Weight and Drug Response in Children—*Mark D. Rapport, George J. DuPaul, and Kevin L. Kelly*

291 Choice of Rating Form for Evaluating Anxiolytics—*Richard I.H. Wang and Carol Kochar*

B1 **Psychopharmacology—A Recurring Bibliography**

CUMULATIVE INDEX
Psychopharmacology Bulletin
A. Contents Index
Vol. 25, No. 3—1989

Annual ACNP Meeting (1989)—Selected Proceedings—

Stress, Neuroendocrine, and Immune Relationships

299 Corticotropin-Releasing Factor (CRF) and Interleukin-1 (IL-1) Receptors in the Brain-Pituitary-Immune Axis—*Errol B. De Souza, Elizabeth L. Webster, Dimitri E. Grigoriadis, and Daniel E. Tracey*

306 Corticotropin-Releasing Factor: Putative Neurotransmitter in the Noradrenergic Nucleus Locus Ceruleus—*Rita J. Valentino*

312 Stress-Responsive Neurohormonal Systems and the Symptom Complex of Affective Illness—*Mitchel A. Kling, Giulia I. Perini, Mark A. Demitrack, Thomas D. Geracioti, Markku Linnoila, George P. Chrousos, and Philip W. Gold*

319 Immune Correlates of Stress and Depression—*Dwight L. Evans, Jane Leserman, Cort A. Pedersen, Robert N. Golden, Mark H. Lewis, James A. Folds, and Howard Ozer*

Implications of Recent Research on Dysthymic Disorders

325 Diagnostic Criteria for Dysthymic Disorder—*Allen Frances, James Kocsis, Deborah Marin, Donna Manning, John Markowitz, Barbara Mason, and Thomas Widiger*

Acute Treatment Response and Short Term Outcome in Schizophrenia

331 Acute Treatment Response and Short Term Outcome in Schizophrenia: First Results of the NIMH Treatment Strategies in Schizophrenia Study—*Nina R. Schooler, Samuel J. Keith, Joanne B. Severe, Susan Matthews, and the Treatment Strategies in Schizophrenia Collaborative Study Group*

336 The Influence of Diagnosis and Family Treatment on Acute Treatment Response and Short Term Outcome in Schizophrenia—*Samuel J. Keith, Alan Bellack, Allen Frances, Rosalind Mance, Susan Matthews, and the Treatment Strategies in Schizophrenia Collaborative Study Group*

340 Demographic Characteristics, Treatment History, Presenting Psychopathology, and Early Course in Schizophrenia—*William A. Hargreaves, John M. Kane, Philip T. Ninan, Joanne B. Severe, Margaret Woerner, and the Treatment Strategies in Schizophrenia Collaborative Study Group*

344 Prediction of Short Term Outcome in Schizophrenia: Depressive Symptoms, Negative Symptoms, and Extrapyramidal Signs—*Ira D. Glick, Marc Jacobs, Jeffrey Lieberman, George Simpson, Nina R. Schooler, and the Treatment Strategies in Schizophrenia Collaborative Study Group*

Neurochemistry and Psychopharmacology in Self-Injurious Behavior

349 Dopaminergic Mechanisms in Self-Inflicting Biting Behavior—*Menek Goldstein*

353 Dopamine Deficiency in Self-Injurious Behavior—*George R. Breese, Hugh E. Criswell, Gary E. Duncan, and Robert A. Mueller*

358 The Differential Diagnosis of Self-Injurious Behavior in Mentally Retarded People—*C. Thomas Gualtieri*

364 Pharmacotherapy for Self-Injurious Behavior: Preliminary Tests of the D_1 Hypothesis—*C. Thomas Gualtieri and Stephen R. Schroeder*

372 Lithium and Propranolol in Aggression and Self-Injurious Behavior in the Mentally Retarded—*Daniel J. Luchins and Denise Dojka*

The Mechanisms of Action of Atypical and Novel Antipsychotic Drugs

377 Actions of Typical and Atypical Antipsychotics on Tuberoinfundibular Dopamine Neurons—*Gary A. Gudelsky, Sally A. Berry, and Herbert Y. Meltzer*

383 The Effects of Clozapine and Fluperlapine on the *in Vivo* Release and Metabolism of Dopamine in the Striatum and in the Prefrontal Cortex of Freely Moving Rats—*Assunta Imperato and Luciano Angelucci*

390 The Ratios of Serotonin$_2$ and Dopamine$_2$ Affinities Differentiate Atypical and Typical Antipsychotic Drugs—*Herbert Y. Meltzer, Shigehiro Matsubara, and Jar-Chi Lee*

393 Partial Brain Dopamine D_2 Receptor Agonists in the Treatment of Schizophrenia—*David Coward, Keith Dixon, Albert Enz, Gary Shearman, Stephan Urwyler, Trevor White, and Manfred Karobath*

Serotonin, Aggression, and Self-Destructive Behavior

399 Brain 5-HT and Inhibition of Aggressive Behavior in Animals: 5-HIAA and Receptor Subtypes—*Klaus A. Miczek, Jan Mos, and Berend Olivier*

404 Monoamines, Glucose Metabolism, and Impulse Control—*Markku Linnoila, Judith DeJong, and Matti Virkkunen*

407 Neurochemical Studies of Violent and Nonviolent Suicide—*J. John Mann, Peter M. Marzuk, Victoria Arango, P. Anne McBride, Andrew C. Leon, and Helen Tierney*

Posttraumatic Stress Disorder: Recent Advances in Basic Science and Clinical Research

415 Introduction—*Jonathan R.T. Davidson*

417 Endogenous Opioids, Stress Induced Analgesia, and Posttraumatic Stress Disorder—*Bessel A. van der Kolk, Mark S. Greenberg, Scott P. Orr, and Roger K. Pitman*

422 Pharmacotherapy in Posttraumatic Stress Disorder: Historical and Clinical Considerations and Future Directions—*Jonathan R.T. Davidson and Charles B. Nemeroff*

426 Psychophysiological Investigations of Posttraumatic Stress Disorder Imagery—*Roger K. Pitman, Scott P. Orr, and Gail S. Steketee*

Affective and Eating Disorders: Appetite, Weight Regulation, and Neuroendocrine Function

433 Contribution of CNS Neuropeptide (NPY, CRH, and Beta-Endorphin) Alterations to Psychophysiological Abnormalities in Anorexia Nervosa—*Walter H. Kaye, Wade H. Berrettini, Harry E. Gwirtsman, Philip W. Gold, David T. George, David C. Jimerson, and Michael H. Ebert*

439 Neurohypophyseal Dysfunction: Implications for the Pathophysiology of Eating Disorders—*Mark A. Demitrack, Michael D. Lesem, Harry A. Brandt, Teresa A. Pigott, David C. Jimerson, Margaret Altemus, and Philip W. Gold*

444 Meal-Related Cholecystokinin Secretion in Eating and Affective Disorders—*Thomas D. Geracioti, Jr., Mitchel A. Kling, Jean R. Joseph-Vanderpool, Shuji Kanayama, Norman E. Rosenthal, Philip W. Gold, and Rodger A. Liddle*

Selected Posters—Summaries

451 Akathisia: Selective β-Blockers and Rating Instruments—*Lenard A. Adler, Erica Duncan, Anthony Kim, Paula Hemdal, John Rotrosen, and Burt Angrist*

457 Serotonergic Aspects of Acute Extrapyramidal Syndromes in Nonhuman Primates—*Daniel E. Casey*

460 Further Observations on the Effects of Subhypnotic Doses of Midazolam in Normal Volunteers—*Edward F. Domino, Jonathan French, Roman Pohorecki, Christopher F. Galus, and Sujit K. Pandit*

466 Effects of Glucocorticoid Antagonism With RU 486 on Pituitary-Adrenal Function in Patients With Major Depression: Time-Dependent Enhancement of Plasma ACTH Secretion—*Mitchel A. Kling, Harvey J. Whitfield, Jr., Harry A. Brandt, Mark A. Demitrack, Konstantine Kalogeras, Thomas D. Geracioti, Giulia I. Perini, Joseph R. Calabrese, George P. Chrousos, and Philip W. Gold*

473 Smooth Pursuit Eye Movements in Schizophrenia: Effects of Neuroleptic Treatment and Caffeine—*Robert E. Litman, Daniel W. Hommer, Thomas Clem, Mark H. Rapaport, Carlos N. Pato, and David Pickar*

479 Plasma Levels of Parent Drug and Metabolites in Patients Receiving Oral and Depot Fluphenazine—*Stephen R. Marder, Theodore Van Putten, Manickam Aravagiri, John W. Hubbard, Edward M. Hawes, Gordon McKay, and Kamal K. Midha*

483 Pharmacokinetics of Desipramine in Asian and Caucasian Volunteers—*Edmond H. Pi, Tram K. Tran-Johnson, Neal R. Walker, Thomas B. Cooper, Raymond F. Suckow, and Gregory E. Gray*

488 Ensuring Data Quality in a Multicenter Clinical Trial: Remote Site Data Entry, Central Coordination and Feedback—*Joanne B. Severe, Nina R. Schooler, J. Hillary Lee, Gretchen Haas, Kim T. Mueser, Phyllis Rosen, DiAnn Shortell, and Martha Shumway*

491 Oculomotor Abnormalities and Their Clinical Correlates in Schizophrenia—*Gunvant Thaker, Brian Kirkpatrick, Robert W. Buchanan, Richard Ellsberry, Adrienne Lahti, and Carol Tamminga*

498 Facilitation of Calcium-Dependent Cholinergic Function by ucb L059, a New "Second Generation" Nootropic Agent—*Ernst Wülfert, Israel Hanin, and René Verloes*

B1 **Psychopharmacology–A Recurring Bibliography**

CUMULATIVE INDEX
Psychopharmacology Bulletin
A. Contents Index
Vol. 25, No. 4—1989

Special Feature—Personality Disorders

505 Introduction—*S. Charles Schulz*

508 Personality Disorders: Issues in Assessment—*Deborah B. Marin, Thomas A. Widiger, Allen J. Frances, Scott Goldsmith, and James Kocsis*

515 Pharmacotherapy of Borderline Personality Disorder: A Review—*David L. Gardner and Rex William Cowdry*

524 Phenelzine, Imipramine, and Placebo in Borderline Patients Meeting Criteria for Atypical Depression—*Bruce Parsons, Frederic M. Quitkin, Patrick J. McGrath, Jonathan W. Stewart, Elaine Tricamo, Katja Ocepek-Welikson, Wilma Harrison, Judith G. Rabkin, Steven G. Wager, and Edward Nunes*

535 Open Assessment of the Safety and Efficacy of Thioridazine in the Treatment of Patients With Borderline Personality Disorder—*Martin H. Teicher, Carol A. Glod, Scott T. Aaronson, Patricia A. Gunter, Alan F. Schatzberg, and Jonathan O. Cole*

550 Prediction of Change in Borderline Personality Disorder—*Solomon C. Goldberg*

556 Rationale for Clinical Trials of Opiate Antagonists in Treating Patients With Personality Disorders and Self-Injurious Behavior—*P. Eric Konicki and S. Charles Schulz*

564 The Role of Pharmacotherapy in the Treatment of Patients With Borderline Personality Disorder—*Michael H. Stone*

572 Measurement of Change in Personality Disorders—*Jean Endicott and M. Tracie Shea*

579 **Cumulative Index—Psychopharmacology Bulletin—1989**

Contents Index
Authors Index

B1 **Psychopharmacology—A Recurring Bibliography**